Kamada Wants To Do More For Organ Transplant Patients, Increases Efforts To Build Awareness Of Its CMV Treatment CYTOGAMSearch for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.
Kamada Wants To Do More For Organ Transplant Patients, Increases Efforts To Build Awareness Of Its CMV Treatment CYTOGAMDETROIT, MICHIGAN - June 6, 2025 ( NEWMEDIAWIRE ) - Cytomegalovirus (CMV) is a common virus that most adults are exposed to at some point in their lives, and over half of American adults have been infected by age 40 . A healthy immune system can keep the virus at bay, and it’s usually harmless. But for organ transplant recipients, contracting CMV disease can be dangerous and even deadly in some cases. About 20% to 60% of people who have a solid organ transplant develop a symptomatic CMV infection. It's one of the most common complications for solid organ transplant recipients. While effective strategies that often use antiviral medicines to prevent or treat CMV exist, none offer a completely foolproof solution, nor is there any vaccine available to prevent it in advance.
Kamada Expects Third Plasma Collection Site To Support Its Hyper-Immune Plasma Needs And Add Up To $10M In Annual Revenue At Full CapacitySearch for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.
Kamada Ltd. (NASDAQ: KMDA) Records 52-Week High Wednesday MorningShares of Kamada Ltd. (
NASDAQ: KMDA) traded at a new 52-week high today and are currently trading at $5.29. So far today, approximately 287.54k shares have been exchanged, as compared to an average 30-day volume of 20,106 shares.
Kamada Is Bringing Relief To Those With Rare And Serious ConditionsSearch for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.
Kamada Is Bringing Relief To Those With Rare And Serious ConditionsDETROIT, MICHIGAN - April 16, 2025 ( NEWMEDIAWIRE ) - Amir London, CEO of Kamada Pharmaceuticals (
NASDAQ: KMDA), was recently a guest on Benzinga’s All-Access.
Sidoti Events, LLC's Virtual March Small-Cap ConferenceNEW YORK CITY, NY / ACCESS Newswire / March 18, 2025 / Sidoti Events, LLC, an affiliate of Sidoti & Company, LLC, has released the presentation schedule and weblinks for its two-day March Small-Cap Conference taking place Wednesday and Thursday, March 19-20, 2025. The presentation schedule is subject to change. Please visit www.sidoti.com/events for the most updated version and webinar links.
Kamada Announces Dividend After Record-Breaking Year, Anticipates Further Double-Digit GrowthSearch for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.
How Kamada (NASDAQ: KMDA) Is Transforming Its Strategic Focus Into Commercial GrowthSearch for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.
